A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies
Authors:
- 9 June 2006
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 59 (2) , 207-215
Abstract
Bortezomib, a selective inhibitor of the 20S proteasome with activity in a variety of cancers, exhibits sequence-dependent synergistic cytotoxicity with taxanes and platinum agents. Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity.Keywords
This publication has 21 references indexed in Scilit:
- THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPYAnnual Review of Pharmacology and Toxicology, 2006
- Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell lineCancer Chemotherapy and Pharmacology, 2004
- Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2004
- In Reply:Journal of Clinical Oncology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucialThe Lancet Oncology, 2001
- Chemosensitization of Pancreatic Cancer by Inhibition of the 26S ProteasomeJournal of Surgical Research, 2001
- How Proteolysis Drives the Cell CycleScience, 1996